ClinicalTrials.gg
CompletedNCT00643968COOLUpdated Jun 30, 2008

Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial

A Phase 4 interventional study of EFV+TDF and EFV+3TC+TDF in HIV Infections, sponsored by Gilead Sciences. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-06-30.

Sponsored by Gilead Sciences · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
66th of 126
140 · median 154
Started
2003
with 2 others
Phase 4
29 of 132
3 open now
Registered
90th of 132
by date
Lead sponsor
4 of 132
Gilead Sciences

Among the 132 studies testing lamivudine in HIV Infections, this one is the 66th largest by enrollment of the 126 interventional ones that give a count, is one of 3 that started in 2003, is one of 29 in phase 4, and was the 90th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (\< 50 copies/mL) (c/mL) at 48 weeks (W48)

Main Secondary objectives:

Comparison of the two arms for genotypic resistance profile in case of virological failure

CD4 changes from baseline

Evolution of the lipid profile and morphological changes in fat distribution, and safety

Efficacy and genotypic profile data, results of lipid markers, morphological changes and main biological parameters

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV virological control
  • Lipid profile and morphological fat distribution
  • Treatment Experienced
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable HAART ≥ 3 months
  • -1 RNA \< 50 c/mL ≥ 6 months
  • No HAART failure history

Exclusion criteria

Exclusion Criteria:

  • Weight > 45 kg
  • No criteria
  • No significant laboratory or clinical abnormalities
  • > 60 mL/min
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Active comparator
    1

    TDF+EFV

    Drug: EFV+TDF

  • Experimental
    2

    TDF+3TC+EFV

    Drug: EFV+3TC+TDF

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48)

    Time frame: 48 wks

Secondary outcomes

  1. Comparison of the two arms for genotypic resistance profile in case of virological failure

    Time frame: 48 wks

  2. CD4 changes from baseline

    Time frame: 48 wks

  3. Evolution of the lipid profile and morphological changes in fat distribution, and safety

    Time frame: 48 wks

07

Study locations

1 site
  • France and French West Indies
    Paris, France
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Jun 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2008
First posted
Mar 26, 2008
Start
Mar 2003
Primary completionActual
Jun 2005
CompletionActual
Sep 2005
Last update
Jun 30, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00643968
Lead sponsor
Gilead Sciences
First posted
Mar 26, 2008
Start date
Mar 2003
Primary completion
Jun 2005
Completion
Sep 2005
Last update
Jun 30, 2008

Study contacts

Aldo Trylesinski, MD
principal investigator · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Tenofovir

Start the discussion